PDS Biotechnology Corporation

What they do

PDS Biotechnology develops targeted immunotherapies for cancer. Its lead program, PDS0301 (formerly PDS01ADC), is an investigational tumor-targeted IL-12 immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment. The company also owns the Versamune platform, including PDS0101, which has been evaluated in HPV16-positive cancers and is now being pursued only through partnerships or external funding.

Revenue drivers

• PDS0301 (tumor-targeted IL-12 immunocytokine) — Lead development program following the strategic refocus; no product revenue is reported, and the company is a clinical-stage business with net losses.
• PDS0101 / Versamune platform — HPV16-positive cancer candidate; internal investment has ceased and the company intends to pursue strategic partnerships or other externally funded opportunities.
• Versamune and Infectimune platforms — Platform technologies referenced in company disclosures; no approved products or product revenue are reported.

Recent performance

For the three months ended June 30, 2026, PDS Biotech reported a net loss of $9.8 million, or $0.18 per basic and diluted share, compared with $9.4 million, or $0.21 per share, for the same period in 2025. Research and development expenses fell to $3.3 million from $4.2 million, and general and administrative expenses were $3.2 million versus $3.4 million. Total operating expenses were $6.5 million compared with $7.6 million. Net interest expense rose to $3.3 million from $1.8 million, primarily due to a non-cash charge for loss on retirement of debt. Cash as of June 30, 2026 was $5.6 million.

Strategy

Management announced a strategic refocus to prioritize PDS0301 as the lead development program. The company will cease further internal investment in PDS0101, including discontinuation of the VERSATILE-003 Phase 3 trial, and intends to pursue strategic partnerships or other externally funded opportunities for PDS0101. Management states it is concentrating capital and development resources on PDS0301 while maintaining financial discipline and preserving PDS0101's potential value through partnerships. The company also completed a financing in September 2026 and reported an unregistered sale of equity, though terms are not detailed in the provided excerpts.

Risks

• Going concern and liquidity — With $5.6 million of cash at June 30, 2026, negative shareholder equity of $3.6 million, and total liabilities of $12.4 million, the company depends on additional financing and its discontinuation of VERSATILE-003 may further impact its ability to continue as a going concern.
• Strategic refocus execution — The recent prioritization of PDS0301 and discontinuation of the PDS0101 Phase 3 trial may not achieve anticipated benefits and involves significant risks and uncertainties.
• Financing dilution and dependency — The company depends on additional financing to fund operations and complete development, and raising capital may restrict operations or require relinquishing rights to technologies or candidates.
• Clinical and regulatory risk — PDS0301 and other candidates remain investigational; timing of trials, FDA approval, and whether results are sufficient to support future success are uncertain.

Outlook

Management says it will prioritize capital and development resources on PDS0301, its tumor-targeted IL-12 immunocytokine. The company intends to pursue strategic partnerships or other externally funded opportunities for the continued development of PDS0101. It has announced positive biomarker and clinical data from a Stage 1 NCI-led metastatic colorectal cancer trial, with ORR of 77.8% (7/9) at six months and an approximately 80% 24-month survival rate. The company describes its strategy as maintaining financial discipline while advancing PDS0301 in indications where its tumor-targeted mechanism may complement established and emerging cancer therapies.